Login
TELA Bio, Inc. logo

TELA Bio, Inc.

telabio.com

What Do They Do?

Sells reinforced tissue matrices for hernia repair and abdominal wall reconstruction, plus soft-tissue repair products for plastic and reconstructive surgery, to hospitals and ambulatory surgery centers.

How Do They Make Money?

Hospitals and other surgical facilities buy products outright. The company is paid when non-consigned products ship or are delivered, and when consigned products are used in a procedure.

FY2025 revenue

Who Are Their Customers?

Sells directly to hospitals and ambulatory surgery centers; outside Europe, it does not use stocking distributors. In Europe, it also sells through distributors.

Do Revenues Turn Into Profits?

No. It lost $38.8M in FY2025.

Operating income, FY2025
−42% of revenue
▲ +1% (Loss) vs FY2024 (−$34.1M, −49%)
Net income, FY2025
−48% of revenue
▼ −3% (Loss) vs FY2024 (−$37.8M, −55%)
Free cash flow, FY2025
−36% of revenue
▲ +33% (Loss) vs FY2024 (−$42.6M, −61%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −8%
vs $20.7M in Q3 FY2025
Net income
▼ −8% (Loss)
vs −$8.6M in Q3 FY2025
  • Oct 5, 2026 FDA cleared TELA Bio's Liora soft-tissue scaffold The resorbable surgical mesh product was the first implant fully developed in the company's Malvern cleanroom.
  • Aug 28, 2026 TELA Bio announced a cost-reduction initiative and CFO departure The company said the initiative would cut annual operating expenses by $17.0 million and extend its cash runway into 2028; CFO Roberto Cuca stepped down.
  • Aug 3, 2026 TELA Bio replaced its CEO Antony Koblish left as CEO and director, and Heather Getz became CEO and a director.

Growing. Revenue grew 2.7x in 4 years, from $29.5M in FY2021 to $80.3M in FY2025, about 28% a year.

Broader PRS product line The latest report describes OviTex PRS with three configurations, including permanent and resorbable polymer options; the older report describes the portfolio without these configurations.

New distribution products The older report describes a surgical wash distributed through a partner and a wound-care product launched with a development partner. The latest report says distribution rights to the wound-care product were sold and describes a hernia fixation device distribution agreement.

Who Do They Compete With?

Competes with Bard, Becton, Dickinson and, Allergan, AbbVie, MTF Biologics, Novadaq, RTI Surgical, and Integra Lifesciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support